Inaprubahan na ng US Food and Drug Administration (FDA) ang paggamit ng experimental antiviral drug na remdesivir.
Dahil dito, nagbigay ng donasyon ang Gilead Sciences ng 1.5 million vials ng remdesivir para sa nasabing testing.
Ayon kay Vice President Mike Pence, magbibigay sila ng nasabing gamot sa mga ospital simula sa Lunes.
Ang nasabing gamot ay unang ginamit sa Ebola na sinasabing maaaring gamitin din sa mga pasyente na kinapitan ng coronavirus symptoms.
“Remdesivir is a direct acting antiviral drug that inhibits viral RNA synthesis. It is an investigational drug and is not currently approved for any indication. Remdesivir has activity in cell culture and animal models against SARS-CoV, MERS-CoV, and SARS-CoV-2. Based on review of the topline data from the randomized, double-blinded, placebo-controlled trial conducted by NIAID (NCT04280705) and from the Gilead-sponsored open-label trial that evaluated different durations of remdesivir (NCT04292899), it is reasonable to believe that theknown and potential benefits of RDV outweigh the known and potential risks of the drug for the treatment of patients hospitalized with severe COVID-19,” bahagi ng sulat ni RADM Denise Hinton, chief scientist ng FDA sa kompaniyang Gilead. “Based on the totality of scientific evidence available to FDA, it is reasonable to believe that remdesivir may be effective in treating COVID-19, and that, when used under the conditions described in this authorization, the known and potential benefits of remdesivir when used to treat COVID-19 outweigh the known and potential risks of such products; and 3.There is no adequate, approved, and available alternative to the emergency use of remdesivir for the treatment of COVID-19.”
